Vnitr Lek 2016, 62(6):474-476

HOPE-3 study: statins reduce cardiovascular events in patients with an intermediate risk of ISHD

Jiří Widimský
Klinika kardiologie IKEM, Praha

The HOPE-3 study focused on identifying the significance of the polypill and mini-polypill in broad clinical practice, including individuals of different gender without cardiovascular diseases with an intermediate risk of cardiovascular diseases. The authors were interested in the question whether people from various antropologhy groups including not only white people but also other antropologhy groups - the blacks, people of Asian and South American origin and more covering 6 continents, would respond in a similar way. The study mainly examined the significance of the mini-polypill, comprising the use of antihypertensive treatment (16 mg candesartan per day + 12.5 mg hydrochlorothiazide), treatment with statins (10 mg rosuvastatin per day), and their combination. The study presents a new way forward in the prevention of cardiovascular diseases, but it also entails some weaknesses which consist in rather rare medical checkups including laboratory tests. Owing to that the concept of mini-polypill has met with some reservation. But it also brings with it reduction of healthcare costs.

Keywords: mini-polypill; prevention of cardiovascular diseases; relevance of statins also to primary prevention

Received: May 3, 2016; Accepted: May 15, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. HOPE-3 study: statins reduce cardiovascular events in patients with an intermediate risk of ISHD. Vnitr Lek. 2016;62(6):474-476.
Download citation

References

  1. Lonn EM, Bosch J, Lopez-Jaramillo P et al. Blood pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374(21): 2009-2020. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600175>. Go to original source... Go to PubMed...
  2. Yusuf S, Bosch J, Zhu J et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374(21): 2021-2031. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600176>. Go to original source... Go to PubMed...
  3. Yusuf S, Lonn E, Prem P et al. Blood-pressure and cholesterol-lowering in persons without cardiovascular disease. N Engl J Med 2016; 374(21): 2032-2043. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600177>. Go to original source... Go to PubMed...
  4. Cushman WC, Goff DC. More HOPE for prevention with statins. N Engl J Med 2016; 374(21):2085-2087. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMe1603504>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.